Erythromycin interaction with risperidone or clomipramine in an adolescent

Journal of Child and Adolescent Psychopharmacology

Volumn 6, Issue 2, 1996, Pages 133-138

  Fisman, Sandra ^a,b   Reniers, Denise ^a   Diaz, Paula ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; ERYTHROMYCIN; ISOENZYME; RISPERIDONE;

ADOLESCENT; AGITATION; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CASE REPORT; COMPULSION; DRUG INTERACTION; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; PROTEIN BINDING;

EID: 0029737054     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.1996.6.133     Document Type: Article

References (19)

1. Alarcon RD, Johnson BR, Lucas JP: Paranoid and aggressive behavior in two obsessive-compulsive adolescents treated with clomipramine. J Am Acad Child Adolesc Psychiat 30:999-1002, 1991
2. Amsden GW: Macrolides versus azalides: A drug interaction update. Ann Pharmacother 29:906-917, 1995
3. Amsterdam JD, Maislin G: Effect of erythromycin on tricyclic antidepressant metabolism. J Clin Psychopharmacol 11:203-206, 1991
4. Cardoni AA: Risperidone: Review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother 29:610-618, 1995
5. Ciba Geigy: Anafranil® product monograph. Mississauga (Ontario, Canada), Ciba Geigy Canada Ltd, 1995
6. Cohen LJ: Risperidone: Pharmacotherapy 14:253-265, 1994
7. Csfík V, Molnár J: Possible adverse interaction between clozapine and ampicillin in an adolescent with schizophrenia. J Child Adolesc Psychopharmacol 4:123-128, 1994
8. DeVane CL: Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiat 55 (Supp):38-45, 1994
9. DeVane CL: Drug interactions and antipsychotic therapy. Pharmacotherapy 16:15S-20S, 1996
10. Gelenberg AJ: The P450 family. Biol Therap Psychiat Newslett 18:29-31, 1995
11. Gonzalez FJ, Nebert DW: Evolution of the P450 gene super family: Animal-plant "warfare", molecular drive and human genetic differences in drug oxidation. Trends Genet 6:182-186, 1990
12. Grant S, Fitton A: Risperidone: A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48:253-273, 1994
13. Janssen Pharmaceutica: Risperdal® product monograph. Mississauga (Ontario, Canada), Janssen Pharmaceutica Inc., 1993
14. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM: The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15:387-398, 1995
15. Riesenman C: Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal. Pharmacotherapy 15:84S-99S, 1995
16. Rosenbaum JF (ed): Drug interactions and the cytochrome P450 system: Clinical implications for selective serotonin reuptake inhibitors. Clin Pharmacokinet 29(Supp 1):1-59, 1995
17. Slaughter RL, Edwards DJ: Recent advances: The cytochrome P450 enzymes. Ann Pharmacother 29:619-624, 1995
18. Wilens TE, Spencer T, Biederman J, Wozniak J, Connor D: Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiat 34:110-112, 1995
19. Zaleon CR, Guthrie SK: Antipsychotic drug use in older adults. Am J Hosp Pharm 51:2917-2943, 1994